Live Breaking News & Updates on Reata Pharmaceuticals Stock

Stay updated with breaking news from Reata pharmaceuticals stock. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Andrea Loewen Sells 3,175 Shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Stock

Reata Pharmaceuticals, Inc. (NASDAQ:RETA – Get Free Report) SVP Andrea Loewen sold 3,175 shares of Reata Pharmaceuticals stock in a transaction dated Thursday, September 14th. The stock was sold at an average price of $172.03, for a total value of $546,195.25. Following the sale, the senior vice president now directly owns 28,416 shares in the […] ....

Andrea Loewen , Leerink Partnrs , Robertw Baird , News Ratings For Reata Pharmaceuticals Daily , Quarter For Reata Pharmaceuticals , Securities Exchange Commission , International Assets Investment Management , Reata Pharmaceuticals , Reata Pharmaceuticals Stock , Reata Pharmaceuticals Company Profile , Belpointe Asset Management , Reata Pharmaceuticals Inc , Visionpoint Advisory Group , Institutional Investors Weigh In On Reata Pharmaceuticals , China Universal Asset Management Co , Get Free Report , Exchange Commission , Asset Management , Assets Investment Management , Universal Asset Management , Point Advisory Group , Strs Ohio , Reata Pharmaceuticals Daily , Nasdaq Reta , Insider Trading , Nsider Trades ,

Reata Pharmaceuticals (NASDAQ:RETA) Hits New 12-Month High at $170.83

Reata Pharmaceuticals, Inc. (NASDAQ:RETA – Get Free Report)’s stock price reached a new 52-week high during trading on Monday . The stock traded as high as $170.83 and last traded at $170.83, with a volume of 25211 shares. The stock had previously closed at $170.32. Analysts Set New Price Targets Several brokerages have issued reports […] ....

Leerink Partnrs , Bhaskar Anand , Manmeet Singh Soni , Reata Pharmaceuticals Inc , China Universal Asset Management Co , International Assets Investment Management , Reata Pharmaceuticals , Reata Pharmaceuticals Company Profile , Visionpoint Advisory Group , Securities Exchange Commission , Reata Pharmaceuticals Stock , News Ratings For Reata Pharmaceuticals Daily , Institutional Trading Of Reata Pharmaceuticals , Belpointe Asset Management , Get Free Report , Singh Soni , Exchange Commission , Asset Management , Assets Investment Management , Point Advisory Group , Universal Asset Management , Strs Ohio , Reata Pharmaceuticals Daily , Nasdaq Reta ,

Cantor Fitzgerald Reiterates Neutral Rating for Reata Pharmaceuticals (NASDAQ:RETA)

Reata Pharmaceuticals (NASDAQ:RETA – Get Free Report)‘s stock had its “neutral” rating reaffirmed by equities researchers at Cantor Fitzgerald in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $172.00 price target on the stock. Cantor Fitzgerald’s target price indicates a potential upside of 1.73% from the company’s previous close. […] ....

New Zealand General , New Zealand , Leerink Partnrs , Manmeet Singh Soni , Carter Bir , First Light Asset Management , Blackrock Inc , Analyst Recommendations For Reata Pharmaceuticals , Reata Pharmaceuticals Stock , Reata Pharmaceuticals Inc , Securities Exchange Commission , Perceptive Advisors , Hedge Funds Weigh In On Reata Pharmaceuticals , Cantor Fitzgerald , Jefferies Financial Group , Vanguard Group Inc , Wellington Management Group , Reata Pharmaceuticals , News Ratings For Reata Pharmaceuticals Daily , Get Free Report , Reata Pharmaceutical , Financial Group , Singh Soni , Dawn Carter Bir , Exchange Commission , Management Group ,

Reata Pharmaceuticals (NASDAQ:RETA) Stock Rating Lowered by Guggenheim

Reata Pharmaceuticals (NASDAQ:RETA – Get Free Report) was downgraded by Guggenheim from a “buy” rating to a “neutral” rating in a note issued to investors on Friday, FlyOnTheWall reports. RETA has been the subject of several other reports. Stifel Nicolaus lowered Reata Pharmaceuticals from a “buy” rating to a “hold” rating in a report on […] ....

Stifel Nicolaus , Manmeet Singh Soni , Michaeld Wortley , Analyst Recommendations For Reata Pharmaceuticals , Reata Pharmaceuticals , Reata Pharmaceuticals Stock , International Assets Investment Management , China Universal Asset Management Co , Belpointe Asset Management , Reata Pharmaceuticals Company Profile , Securities Exchange Commission , Reata Pharmaceuticals Inc , News Ratings For Reata Pharmaceuticals Daily , Insider Activity At Reata Pharmaceuticals , Advisor Group Holdings Inc , Us Bancorp , Get Free Report , Exchange Commission , Singh Soni , Asset Management , Assets Investment Management , Universal Asset Management , Group Holdings , Reata Pharmaceuticals Daily , Nasdaq Reta ,

Cantor Fitzgerald Boosts Reata Pharmaceuticals (NASDAQ:RETA) Price Target to $145.00

Reata Pharmaceuticals (NASDAQ:RETA – Get Free Report) had its price target boosted by investment analysts at Cantor Fitzgerald from $110.00 to $145.00 in a research note issued to investors on Monday, FlyOnTheWall reports. Cantor Fitzgerald’s price objective would suggest a potential upside of 30.80% from the stock’s current price. Other research analysts have also recently […] ....

United States , Manmeet Singh Soni , Stifel Nicolaus , Bhaskar Anand , Highmark Wealth Management , Emerald Advisers , Cantor Fitzgerald , Hedge Funds Weigh In On Reata Pharmaceuticals , News Ratings For Reata Pharmaceuticals Daily , Reata Pharmaceuticals Stock , Analyst Recommendations For Reata Pharmaceuticals , Securities Exchange Commission , Reata Pharmaceuticals , Emerald Mutual Fund Advisers , Reata Pharmaceuticals Inc , First Light Asset Management , Reata Pharmaceuticals Company Profile , Get Free Report , Singh Soni , Exchange Commission , Mark Wealth Management , Mutual Fund Advisers Trust , Light Asset Management , Reata Pharmaceuticals Daily , Nasdaq Reta , Boost Price Target ,